fostamatinib disodium · Rigel Pharms · NDA 209299

Tavalisse

Earliest generic entry, as listed · earliest of 2 marketed strengths
27 Jul 2032

Blocked by patent: US 8771648, US 8951504.

FDA has approved 1 generic application (ANDA) for Tavalisse, though its earliest generic-entry date is 27 Jul 2032 as listed. A generic can be approved before that date when it leaves out a patented use (a section viii carve-out), challenges a patent, or settles with the brand company. An approval is not a launch: cliffwatch does not track launches. Approval is not launch

Listed patents · 5 unexpired

PatentClaimsExpires
US 8771648drug product · sets the listed date27 Jul 2032
US 8951504use U-2294 · sets the listed date27 Jul 2032
US 7449458drug substance4 Sep 2031
US 8263122drug product24 Nov 2030
US 8652492drug product6 Nov 2028

Exclusivities · 0 unexpired

No unexpired exclusivities listed.

Paragraph IV certifications · 0

No Paragraph IV certification listed by FDA for this drug.

The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.

Event history

  • First generic approved · ANDA 217329, Annora Pharma · 209299-001Approved 17 Jun 2026Detected 25 Oct 2026Historical import
  • Generic approved · ANDA 217329, Annora Pharma · 209299-001Approved 17 Jun 2026Detected 25 Oct 2026Historical import

Products covered · 2

NDA · productFormStrengthListed expiry
209299 · 001 · RLDtablet, oralEQ 100MG BASE27 Jul 2032
209299 · 002 · RLDtablet, oralEQ 150MG BASE27 Jul 2032
Expired or delisted (9)
  • US 8163902 · substance, use U-2294 · 17 Jun 2026
  • US 8445485 · product · 17 Jun 2026
  • US 8912170 · use U-2294 · 17 Jun 2026
  • US 9283238 · use U-2294 · 17 Jun 2026
  • US 7989448 · substance, use U-2294 · 12 Jun 2026
  • US 7538108 · substance, use U-2294 · 28 Mar 2026
  • US 8211889 · substance · 19 Jan 2026
  • US 9266912 · use U-2294 · 19 Jan 2026
  • US RE48898 · product · 19 Jan 2026